

From the LipidSpin Editor

1. Ference BA, Graham I, Tokgozoglul L et al. Impact of Lipids on Cardiovascular Health, *JACC* 2018;72:1141-56
2. Bleich SN; A Road Map for Sustaining Healthy Eating Behavior, *N Engl J Med*. 2018; 379:507-509

Clinical Feature

1. Berg K. A New Serum Type System in Man – the Lp System. *Acta Pathol Microbiol Scand*. 1963;59:369-382.
2. Ellis KL, Boffa MB, Sahebkar A, Koschinsky ML, Watts GF. The renaissance of lipoprotein(a): Brave new world for preventive cardiology? *Prog Lipid Res*. 2017;68:57-82.
3. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. *Nature*. 1987;330(6144):132-137.
4. Taleb A, Witztum JL, Tsimikas S. Oxidized phospholipids on ApoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. *Biomark Med*. 2011;5(5):673-694.
5. Yeang C, Wilkinson MJ, Tsimikas S. Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis. *Curr Opin Cardiol*. 2016;31(4):440-450.
6. Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. *J Am Coll Cardiol*. 2017;69(6):692-711.
7. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. *N Engl J Med*. 2009;361(26):2518-2528.
8. Thanassoulis G. Lipoprotein(a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis. *J Lipid Res*. 2016;57(6):917-924.
9. Scipione CA, Koschinsky ML, Boffa MB. Lipoprotein(a) in clinical practice: New perspectives from basic and translational science. *Crit Rev Clin Lab Sci*. 2018;55(1):33-54.
10. Boffa MB, Koschinsky ML. Lipoprotein(a): truly a direct prothrombotic factor in cardiovascular disease? *J Lipid Res*. 2016;57(5):745-757.
11. Mathieu P, Arsenault BJ, Boulanger MC, Bosse Y, Koschinsky ML. Pathobiology of Lp(a) in calcific aortic valve disease. *Expert Rev Cardiovasc Ther*. 2017;15(10):797-807.
12. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. *Eur Heart J*. 2016;37(39):2999-3058.
13. Yeang C, Witztum JL, Tsimikas S. 'LDL-C' = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. *Curr Opin Lipidol*. 2015;26(3):169-178.
14. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. *JAMA*. 2009;302(4):412-423.
15. Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. *J Lipid Res*. 2016;57(4):526-537.
16. Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. *J Am Coll Cardiol*. 2014;64(9):851-860.
17. Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). *Circulation*. 2014;129(6):635-642.

18. Chasman DI, Shiffman D, Zee RY, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. *Atherosclerosis*. 2009;203(2):371-376.
19. Schwartz GG, Ballantyne CM, Barter PJ, et al. Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: Analysis of the dal-outcomes randomized clinical trial. *JAMA Cardiology*. 2018;3(2):164-168.
20. Nestel PJ, Barnes EH, Tonkin AM, et al. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. *Arterioscler Thromb Vasc Biol*. 2013;33(12):2902-2908.
21. van Capelleveve JC, van der Valk FM, Stroes ES. Current therapies for lowering lipoprotein (a). *J Lipid Res*. 2016;57(9):1612-1618.
22. Jaeger BR, Richter Y, Nagel D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. *Nat Clin Pract Cardiovasc Med*. 2009;6(3):229-239.
23. Leebmann J, Roeseler E, Julius U, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. *Circulation*. 2013;128(24):2567-2576.
24. Roeseler E, Julius U, Heigl F, et al. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apo(a) Characterization. *Arterioscler Thromb Vasc Biol*. 2016;36(9):2019-2027.
25. O'Donoghue ML, Giugliano RP, Keech A. Lipoprotein(a), PCSK9 inhibition and cardiovascular risk: insights from the Fourier Trial. 86th Congress of the European Atherosclerosis Society, Lisbon, Portugal, May 7th 2018.
26. Bittner V. Lp(a) and Cardiovascular Outcomes: an Analysis from the ODYSSEY OUTCOMES Trial. 18th International Symposium on Atherosclerosis, Toronto, Canada, June 12th 2018.
27. Viney NJ, van Capelleveve JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. *Lancet*. 2016;388(10057):2239-2253.

Guest Editorial

1. Araújo-Vilar D, Santini F. Diagnosis and treatment of lipodystrophy: a step-by-step approach. *J Endocrinol Invest*. 2018 Apr 27. doi: 10.1007/s40618-018-0887-z. [Epub ahead of print] PubMed PMID: 29704234
2. Chiquette E, Oral EA, Garg A, Araújo-Vilar D, Dhankhar P. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. *Diabetes Metab Syndr Obes*. 2017 Sep 13;10:375-383. doi: 10.2147/DMSO.S130810. eCollection 2017. PubMed PMID: 29066925; PubMed Central PMCID: PMC5604558.
3. Hussain I, Garg A. Lipodystrophy Syndromes. *Endocrinol Metab Clin North Am*. 2016 Dec;45(4):783-797. doi: 10.1016/j.ecl.2016.06.012. Epub 2016 Oct 6. Review. PubMed PMID: 27823605.
4. Handelsman Y, Oral EA, Bloomgarden ZT, et al. The clinical approach to the detection of lipodystrophy: an AACE consensus statement. *Endocr Pract*. 2013;19(1):107-116.
5. Myalept (metreleptin) Aegerion Pharmaceuticals Full Prescribing Information, Revised 09/2015
6. Stroes E, Moulin P, Parhofer KG, et al. Diagnostic algorithm for familial chylomicronemia syndrome. *Atherosclerosis Supplements* 2017;23:1-7.

EBM Tools for Practice

1. Praluent (Alirocumab) package insert, Sanofi-Aventis, Regeneron, September 2017.
2. Repatha (Evolocumab) package insert, Amgen, December 2017.
3. Orringer CE, Jacobson TA, Saseen JJ, et al. (2017). Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. *J Clin Lipidol*. 2017;11(4):880-890. doi:10.1016/j.jacl.2017.05.001
4. Foltz IN, Karow M, Wasserman SM. Evolution and Emergence of Therapeutic Monoclonal Antibodies: What Cardiologists Need to Know. *Circulation*. 2013;127(22):2222-2230. doi:10.1161/circulationaha.113.002033.
5. U.S. Department of Health and Human Services. Guidance for Industry, Immunogenicity Assessment for Therapeutic Protein Products. 2014. fda.gov/downloads/drugs/guidances/ucm338856.pdf
6. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *N Engl J Med*. 2017;376(18):1713-1722. doi:10.1056/nejmoa1615664
7. McKenney JM. (2015). Understanding PCSK9 and anti-PCSK9 therapies. *J Clin Lipidol*. 2015;9(2):170-186. doi:10.1016/j.jacl.2015.01.001
8. Sabatine MS, Giugliano RP, Wiviott SD, et al. (2015). Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. *N Engl J Med*. 2015;372(16):1500-1509. doi:10.1056/nejmoa1500858
9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. *N Engl J Med*. 2015; 372(16):1489-1499. doi:10.1056/nejmoa1501031
10. Gugliano RP, Mach F, Zavitz K, et al. Primary results of EBBINGHAUS, a cognitive study of patients enrolled in the FOURIER trial. American College of Cardiology 2017 Scientific Sessions: March 18, 2017; Washington, D.C. Abstract 17-LB-16161-AC.
11. Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Privation by Aggressive Reduction in Cholesterol Levels Study. *Neurology*. 008;70(24 Pt 2):2364-70.
12. LaRosa JC, et al [A1]. *Am J Cardiol*. 2013;111:1221-9.
13. Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults with Hypercholesterolemia. *Annals of Internal Medicine*. 2015;163(1):40. doi:10.7326/m14-2957
14. F[A2] urther Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk. (n.d.). Retrieved from clinicaltrials.gov/ct2/show/NCT01764633
15. O[A3] DYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment with Alirocumab. Retrieved from <https://clinicaltrials.gov/ct2/show/NCT01663402>
16. T[A4] he Evaluation of Bococizumab (PF-04950615:RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects. Retrieved from clinicaltrials.gov/ct2/show/NCT01975376
17. The Evaluation of Bococizumab (PF-04950615:RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects. Retrieved from clinicaltrials.gov/ct2/show/NCT01975389
18. Schwartz GG, Bessac L, Berdan LG, et al. (2014). Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial. *Am Heart J*. 2014;168(5). doi:10.1016/j.ahj.2014.07.028
19. Knowles JW, Howard WB, Karayan L, et al. Access to non-statin lipid-lowering therapies in patients at high-risk of atherosclerotic cardiovascular disease. *Circulation*. 2017;135:2204-2206.

20. Cohen JD, Cziraky MJ, Jacobson TA, Maki KC, Karalis DG. Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of the healthcare provider survey conducted by the National Lipid Association. *J Clin Lipidol*. 2017. (published ahead of print; accessed at lipid.org, July 29, 2017).
21. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. *Circulation*. 2014;129(suppl 2):S1-S45.
22. International Atherosclerosis Society position paper: Global recommendations for management of dyslipidemia. athero.org (accessed July 29, 2017).
23. Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: A scientific statement from the American Heart Association. *Circulation*. 2015;132:2167-2192.
24. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1-full report. *J Clin Lipidol*. 2015;9:129-169.
25. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey on 10,138 current and former statin users. *J Clin Lipidol*. 2012;6:208-15.
26. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: A cohort study. *Ann Intern Med*. 2013;158:526-534.
27. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC Expert Consensus Decision Pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol*. 2016;68:92-125.
28. Werner RM, Pearson TA. LDL-cholesterol: a risk factor for coronary artery disease – from epidemiology to clinical trials. *Can J Cardiol*. 1998 May;14 Suppl B:3B-10B.
29. Bhatt D. Cardiac exercise testing: What it can and cannot tell you. *Harvard's Men's Health Watch*. March 18, 2016. <https://www.health.harvard.edu/heart-disease-overview/cardiac-exercise-stress-testing-what-it-can-and-cannot-tell-you>.
30. Cannon CP, Braunwald E, McCabe CH, et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy – Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. *N Engl J Med*. 2004;350:1495-04.
31. Abela GS, Aziz K. Cholesterol crystals rupture biological membranes and human plaques during acute cardiovascular events: A novel insight into plaque rupture by scanning electron microscopy. *Scanning*. 2006;28:1-10.
32. Lundber B. Chemical composition and physical state of lipid deposits in atherosclerosis. *Atherosclerosis*. 1985;56:93-110.
33. Abela GS. Cholesterol crystals piercing the arterial plaque and intima triggers local and systemic inflammation. *J Clin Lipidol*. 2010;4:156-64.
34. Abela GS, Aziz K, Vedre A, et al. Effect of cholesterol crystals on plaques and intima in arteries of patients with acute coronary and cerebrovascular syndromes. *Am J Cardiol*. 2009;103:959-68.
35. Nasiri M, Huang R, Janoud A, et al. Unraveling the Role of Cholesterol Crystals in Plaque Rupture by Altering the Method of Tissue Preparation. *Microsc Res Tech*. 2015;78:969-74.
36. Vedre A, Pathak DR, Crimp M, Lum C, Koochesfahani M, Abela GS. Physical Factors that Trigger Cholesterol Crystallization Leading to Plaque Rupture. *Atherosclerosis*. 2009;203:89-96.
37. Franklin BA, George P, Henry R, Gordon S, Timmis GC, O'Neill WW. Acute myocardial infarction after manual or automated snow removal. *Am J Cardiol*. 2001;87:1282-3.
38. Auda Fares. Winter Cardiovascular Diseases Phenomenon. *N Am J Med Sci*. 2013;5: 266-79.
39. Düwell P, Kono H, Rayner KJ, et al. E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease. *Nature*. 2010;464:1357-62.
40. Janoudi A, Shamoun FE, Kalavakunta JK, et al. Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque. *Euro Heart J* 2016;37:1959-67.
41. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *N Engl J Med* 2017;377:1119-31.
42. Abela GS, Kalavakunta JK, Janoudi A, et al. Frequency of Cholesterol Crystals in Culprit Coronary Artery Aspirate During Acute Myocardial Infarction and Their Relation to Inflammation and Myocardial Injury. *Am J Cardiol*. 2017;120:1699-07.
43. Dey S, Flather MD, Devlin G, et al. Global Registry of Acute Coronary Events investigators. Sex-related differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. *Heart*. 2009;95:20-6.
44. Arbustini E, Dal Bello B, Morbini P, et al. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. *Heart*. 1999;82:269-272.
45. Ota H, Reeves MJ, Zhu DC, et al. Sex differences in patients with asymptomatic carotid atherosclerotic plaque: in vivo 3.0-T magnetic resonance study. *Stroke*. 2010;41:1630-5.
46. Gadeela N, Rubinstein J, Tamhane U, et al. The impact of circulating cholesterol crystals on vasomotor function: Implications for no-reflow[30] [GA31] phenomenon. *J Am Coll Cardiol-Inv*. 2011;4:521-29.
47. Ghanem F, Vodnala D, Kalavakunta JK, et al. Cholesterol crystal embolization following plaque rupture: a systemic disease with unusual features. *J Biomed Res*. 2017;31:82-94.
48. Schwartz RS, Burke A, Farb A, et al. Microemboli and microvascular obstruction in acute coronary thrombosis and sudden coronary death: relation to epicardial plaque histopathology. *J Am Coll Cardiol*. 2009;54:2167-73.
49. Pervaz MH, Durga S, Janoudi A, et al. PET/CTA detection of muscle inflammation related to cholesterol crystal emboli without arterial obstruction. *J Nuc Cardiol*. 2018;25:433-440.
50. Schwartz Rapp JH, Pan XM, Neumann M, Hong M, Hollenbeck K, Liu J. Microemboli composed of cholesterol crystals disrupt the blood brain barrier and reduce cognition. *Stroke*. 2008;39:2354-61.
51. Niccoli G, Scalone G, Lerman A, Crea F. Coronary microvascular obstruction in acute myocardial infarction. *Eur Heart J*. 2016;37:1024-33.
52. Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. *Circ Res*. 2017;120:229-43.
53. Abela GS, Vedre A, Janoudi A, Huang R, Durga S, Tamhane U. Effect of Statins on Cholesterol Crystallization and Atherosclerotic Plaque Stabilization. *Am J Cardiol*. 2011;107:1710-17.
54. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. *J Am Coll Cardiol*. 2007;49:1272-8.
55. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: a randomized controlled trial. *JAMA*. 2001;285:1711-1718.
56. Patel R, Janoudi A, Vedre A, et al. Plaque Rupture and Thrombosis is Reduced by Lowering Cholesterol Levels and Crystallization with Ezetimibe and is Correlated with FDG-PET. *Arterioscler Thromb Vasc Biol*. 2011;31:2007-14.
57. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. *Lancet*. 1988;2:349-60.
58. Vedre A, Aziz K, Huang R, Abela GS. Aspirin Prevents Cholesterol Crystallization: A Potential Mechanism of Plaque Stabilization. *J Am Coll Cardiol*. 2008;51: Suppl A, 318.
59. Adams CWM, Abdulla[32] YH[GA33]. The action of human high-density lipoprotein on cholesterol crystals. *Atherosclerosis*. 1978;31:465-71.
60. Narisetty K, Janoudi A, Abela OG, Khan SR, Huang R, Abela GS. The effect of high density lipoprotein on solubility of cholesterol crystals. *J Am Coll Cardiol*. 2011;57: Suppl A, 276.
61. Fernández-Jarne E, Martínez-Losa E, Serrano-Martínez M, et al. Type of alcoholic beverage and first acute myocardial infarction: a case control study in a Mediterranean country. *Clin Cardiol*. 2003;26:313-18.
62. Durga S, Vodnala D, Xie Y, Abela GS. Effect of stress-related catecholamine levels on cholesterol crystallization and plaque rupture. *J Am Coll Cardiol*. 2011;57:Suppl A113..

Lipid Luminations

1. Jacobson TA, Ito, MK, Maki, KC, et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1. *J Clin Lipidol*. 2015;9:129-169.
2. Valdivielso P, Ramirez-Bueno A, Nils E. Current Knowledge of Hypertriglyceridemic Pancreatitis. *EJIM*. 2014;25:8,689-694.
3. Stros E, Moulin, P, Parhofer, K, et al. Diagnostic Algorithm for Familial Chylomicronemia Syndrome. *Atherosclerosis Supplements* 23. 2017;1-7.
4. Nawaz H, Koutroumpakis E., Easler J, et al. Elevated Serum Triglycerides are Independently Associated With Persistent Organ Failure in Acute Pancreatitis. *Am J Gastroenterol*. 2015;110:1497-1503.
5. Gaudet D, de Wal J, Tremblay K, et al. Review of the Clinical Development of Alipogene Tiparovec Gene Therapy for Lipoprotein Lipase Deficiency. *Atherosclerosis Supplements* 11. 2010; 55-60.
6. Brahm AJ, Hegele RA. Chylomicronemia — Current Diagnosis and Future Therapies. *Nat Rev Endocrinol*. 2015;11:352-362.
7. Brinton E. Clinical Management of Hypertriglyceridemia, presented at National Lipid Association Clinical Lipid Update 2015.
8. Davidson M, Stevenson M, Hsieh A, Ahmad Z, Witztum JL. The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study. *Expert Rev Cardiovasc Ther*. 2017;15(5):415-423.
9. Chan DC. An ABC of apolipoprotein C-III: A clinically useful new cardiovascular risk factor? *Int J Clin Pract*. 2008;62(5):799-809.
10. Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the FCS. *NEJM*. 2014;371(23):2200-2206.
11. Gordts PL, Nock, R, Son, N, et al. ApoC-III Inhibits Clearance of TG-Rich Lipoproteins Through LDL Family Receptors. *J Clin Invest*. 2016;126(8):2855-2866.
12. Phase 3 Safety and Efficacy Pivotal Study — Study ISIS 304801-CS6. Alcea Briefing Information for the May 10, 2018, Meeting of FDA Advisory Committee: Endocrine and Metabolic Drugs Advisory Committee.

Science Corner

1. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. *Circulation*. 1989;79:733-43.
2. Mittleman M, Maclure M, Sherwood JB, et al. Triggering of Acute Myocardial Infarction Onset by Episodes of Anger. *Circulation*. 1995;92:1720-25.